Key Highlights
• HCW Biologics eliminated a $2.8 million disputed payable through a settlement finalized by June 30 2026.
• A final Satisfaction of Lien erased a $1.1 million mechanics lien on the 3300 Corporate Way renovation site.
• The company reduced a $1.7 million liability to $1.2 million and paid two installments of $620,000 each to EirGenix.
HCW Biologics Inc. (NASDAQ: HCWB) reported the resolution of two significant legal matters that had generated liabilities on its balance sheet. The settlements, disclosed for the quarter ending June 30 2026, remove a $2.8 million dispute and a $1.1 million lien, thereby strengthening the firm’s financial position ahead of upcoming reporting cycles.
Dispute Extinguishment
HCW Biologics cleared a $2.8 million contested payable after a voluntary dismissal with prejudice was filed by B&I Contractors, Inc. On June 26 2026. The filing eliminated all cross‑claims brought by B&I in the Florida circuit court case, effectively ending the dispute. This development is a core component of the company’s broader effort to resolve outstanding obligations.
Mechanics Lien Resolution
The same legal action removed a mechanics lien valued at $1.1 million that had been placed on the company’s Miramar renovation project at 3300 Corporate Way. The lien originated from unpaid invoices linked to the property’s ongoing office and laboratory upgrades. The final Satisfaction of Lien, submitted alongside the dismissal, confirms that the lien has been fully discharged.
Settlement with B&I Contractors
B&I Contractors, Inc. Submitted the final Satisfaction of Lien together with its voluntary dismissal, signaling that the settlement agreement between the parties is complete. The agreement addressed all amounts previously owed, and with the lien’s removal, no further claims remain pending. This resolution removes uncertainty around the Miramar site’s financial encumbrances.
EirGenix Manufacturing Settlement
In a separate agreement dated December 9 2025, HCW Biologics and contract development manufacturer EirGenix, Inc. Agreed to lower a $1.7 million obligation to $1.2 million, provided payment was made by a mutually selected deadline. The company satisfied this condition with two payments of $620,000 each, first on March 3 2026 and again on May 26 2026. Completion of these payments fulfilled all outstanding invoices and disputed credits with EirGenix.
Financial Impact
The resolution of the $2.8 million dispute and the $1.1 million lien clarifies HCW Biologics’ liability profile for the current reporting period. By eliminating these obligations, the firm improves its balance‑sheet metrics and positions itself for smoother compliance with Nasdaq’s bid‑price standards. The cleared liabilities also provide greater flexibility for future capital allocation and operational initiatives.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.






Please wait processing your request...